This post was originally published on this site
Wedbush initiated coverage on Datadog (NASDAQ:DDOG) with an Outperform rating and a price target of $101.00.
Goldman Sachs initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with a Sell rating and a price target of $35.00, noting it believes that maturing key franchises put intermediate term consensus growth assumptions at risk.
Exane BNP Paribas initiated coverage on Equinix (NASDAQ:EQIX) with an Outperform rating and a price target of $886.00.
Raymond James initiated coverage on POINT Biopharma Global Inc (NASDAQ:PNT) with an Outperform rating and a price target of $10.00.
Goldman Sachs initiated coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and a price target of $60.00. The analysts see near-to-medium-term stock performance driven primarily by updates on XEN1101 in FOS, which they view as a largely de-risked lead indication.
Want to get this news first? Upgrade to InvestingPro for real-time market coverage.
